Latest stories on IMVT
Immunovant Q1 2027 Earnings Preview
Seeking Alpha50 · neutralearnings
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
Seeking Alpha65 · bullishanalyst
S&P 500 Futures Drop in Premarket Trading; ON Semiconductor, DaVita Lag
Barron's42 · neutralgeneral
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Yahoo Top61 · neutralanalyst
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Yahoo Top56 · neutralanalyst
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Seeking Alpha61 · neutralanalyst
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial
Yahoo Top78 · bullishproduct/pr
IMVT: [144] Immunovant, Inc. SEC Filing
StockTitan SEC50 · neutralgeneral
Can a New Arthritis Drug Make Immunovant the Next Biotech Star?
Yahoo Top67 · bullishproduct/pr
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Barron's73 · bullishproduct/pr
This Is Why Immunovant Stock (IMVT) Is Up Today
TipRanks57 · neutralgeneral
IMVT-1402 Shows 72.7% Response Rate at Week 16 in Challenging RA Patients: Immunovant Preps for Key Data in 2026
MarketChameleon73 · bullishproduct/pr
Immunovant Stock Surges 22% on Trial Data. Earnings Are an Afterthought.
Barron's73 · bullishproduct/pr
Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)
Yahoo Top58 · neutralproduct/pr
Micron, Intel, Lowe’s, Nvidia, Target, Cava, Immunovant, and More Stock Market Movers
Barron's58 · neutralgeneral
S&P 500 Futures Rise in Premarket Trading; Immunovant, ImmunityBio Lead
Barron's68 · bullishgeneral
IMVT-1402 Achieves 72.7% Response Rate in Difficult-to-Treat RA as Immunovant Prioritizes Pipeline Progress
MarketChameleon67 · bullishproduct/pr
Immunovant Q4 2026 Earnings Preview
Seeking Alpha50 · neutralearnings